KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Biogen (BIIB) EBIAT (2016 - 2025)

Historic EBIAT for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to -$48.9 million.

  • Biogen's EBIAT fell 11833.52% to -$48.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 billion, marking a year-over-year decrease of 2078.79%. This contributed to the annual value of $1.3 billion for FY2025, which is 2078.79% down from last year.
  • Latest data reveals that Biogen reported EBIAT of -$48.9 million as of Q4 2025, which was down 11833.52% from $466.5 million recorded in Q3 2025.
  • Biogen's EBIAT's 5-year high stood at $1.1 billion during Q3 2022, with a 5-year trough of -$68.3 million in Q3 2023.
  • In the last 5 years, Biogen's EBIAT had a median value of $391.0 million in 2024 and averaged $444.0 million.
  • Its EBIAT has fluctuated over the past 5 years, first surged by 278487.8% in 2022, then crashed by 11833.52% in 2025.
  • Quarter analysis of 5 years shows Biogen's EBIAT stood at -$20.5 million in 2021, then surged by 2784.88% to $550.4 million in 2022, then tumbled by 54.78% to $248.9 million in 2023, then increased by 7.15% to $266.7 million in 2024, then crashed by 118.34% to -$48.9 million in 2025.
  • Its EBIAT stands at -$48.9 million for Q4 2025, versus $466.5 million for Q3 2025 and $634.8 million for Q2 2025.